ArticleWorld journal of urology2026
HALP score as a predictor of biochemical recurrence after robot-assisted laparoscopic prostatectomy for localized prostate cancer.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the predictive value of the HALP score for biochemical recurrence (BCR) (BCR) (defined as PSA > 0.2 ng/mL) in patients with localized prostate cancer (PCa) who underwent robotic-assisted laparoscopic prostatectomy (RALP), with a minimum follow-up of two years.
methodsThe study recorded preoperative variables such as age, body mass index (BMI), serum total PSA, hemoglobin, albumin, lymphocyte, leukocyte, platelet, and neutrophil counts, International Society of Urological Pathology (ISUP) grade, and clinical stage. Serial PSA measurements were taken at various points post-surgery (1, 3, 6, 9, 12, 15, 18, 24 months). BCR was defined as a PSA increase > 0.2 ng/mL. The HALP score was calculated using the formula: Hemoglobin (g/L) × Albumin (g/L) × Lymphocyte Count (/L) ÷ Platelet Count (/L). It was compared between patients who experienced BCR (BCR group) and those who did not (non-BCR group).
resultsA total of 798 patients were included, with 133 (16.6%) developing BCR. The BCR group had significantly lower preoperative HALP scores (2.3 ± 1.0 vs. 6.0 ± 2.2, p < 0.001) and higher preoperative PSA levels (12.0 vs. 8.0 ng/mL, p < 0.001). Additionally, albumin levels were lower, and platelet counts higher in the BCR group (both p < 0.001). High-grade tumors (ISUP Grade 3–5) were more frequent in the BCR group (42.2% vs. 6.4%, p < 0.001).
conclusionThe HALP score appears to be a promising predictive marker for biochemical recurrence in localized PCa patients post-surgery. As a simple and cost-effective biomarker, it may help identify those at higher risk of recurrence after treatment.
Indexed as
Identifiers
42001337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.